tailieunhanh - Báo cáo y học: "Treatment of stasis dermatitis using aminaphtone: Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Treatment of stasis dermatitis using aminaphtone: Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. | Ceccarelli et al. Journal of Medical Case Reports 2011 5 70 http content 5 1 70 JOURNALOF medical Ur Case REPORTS CASE REPORT Open Access Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir a case report and review of the literature 1 1 2 1 1 Giancarlo Ceccarelli Gabriella d Ettorre Francesco Marchetti Cecilia Rizza Claudio M Mastroianni Bruno Carlesimo2 Vincenzo Vullo1 Abstract Introduction The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact this new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have a good safety profile coupled with potent antiviral activity and their combined use would avert nucleoside- and ritonavir-related toxicities. Case presentation We describe the case of a 47-year-old Caucasian woman treated for HIV-1 infection who developed Buffalo Hump during antiretroviral therapy including raltegravir and unboosted atazanavir. Clinical evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump cannot be attributed to hypercortisolism insulin-resistance diabetes dyslipidemia hyperlactatemia and metabolic syndrome were not present. Moreover she was not in therapy with antiretroviral drugs that are described as the cause of Buffalo Hump on the other hand she developed this side effect three months after the switch of the antiretroviral therapy to raltegravir plus unboosted atazanavir. Conclusion Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely multifactorial a possible contributing cause but not the main cause could be exposure to antiretroviral .